Wyeth Farma SA

To evaluate the occurrence of medically important events (FVIII inhibitor formation) in hemophilia A subjects receiving Renjie in the routine treatment setting in China. Secondary objective: To evaluate the overall safety (including AE and SAE incidence) of Renjie in hemophilia A subjects receiving Renjie in general medical institutions in China and the effectiveness of Renjie for on-demand treatment and surgical prophylaxis. Exploratory objective: To evaluate patient-reported outcomes in pediatric subjects receiving on-demand treatment.

Primary objective: To determine the single-dose pharmacokinetic characteristics of Befu in Chinese male subjects with hemophilia B Secondary objective: To evaluate the single-dose safety and tolerability of Befu in Chinese male subjects with hemophilia B

Primary objective: To evaluate the incidence and severity of medically important events (FIX inhibitor development, allergic reactions, thrombosis) in subjects with hemophilia B receiving bevacizumab under routine medical conditions in China. Secondary objective: To evaluate the overall safety (including AE and SAE incidence) and efficacy of bevacizumab in subjects with hemophilia B under routine medical conditions in China. Exploratory objective: To evaluate patient-reported outcomes in pediatric subjects.